News from isis pharmaceuticals inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 30, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What:   Corporate presentation at its 2015 Annual...

Jun 29, 2015, 14:41 ET
Isis Pharmaceuticals, Inc.

ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has been added to the Russell 1000 Index, effective June 26, 2015. The...

Jun 22, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Reports Data from ISIS-SMN Rx in Children with Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on children with spinal muscular atrophy (SMA) who have completed the...

Jun 16, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Present a General Corporate Update at its 2015 Annual Meeting of Stockholders and Open House

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a general...

Jun 11, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Reports Data from ISIS-SMN Rx Phase 2 Study in Infants with Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMNRx in infants...

Jun 10, 2015, 17:30 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Host Webcast to Discuss Data From ISIS-SMN Rx Phase 2 Study in Infants With Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Thursday, June 11 at 8:30 a.m. Eastern Time to...

Jun 05, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals' License Agreement with Bayer for ISIS-FXI Rx Receives Hart-Scott-Rodino Approval

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its license agreement with Bayer HealthCare (Bayer) to develop and commercialize...

Jun 04, 2015, 18:11 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Present at the Goldman Sachs 36th Annual Global Healthcare Conference

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...

May 28, 2015, 16:00 ET
Isis Pharmaceuticals, Inc.

Webcast Alert: Akcea Therapeutics Conference Call

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Akcea Therapeutics Webcast When: Thursday,...

May 05, 2015, 10:00 ET
Isis Pharmaceuticals, Inc

Isis Reports Financial Results and Highlights for First Quarter 2015

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported pro forma operating income of $4.0 million for the three months ended March 31, 2015...

May 04, 2015, 09:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) has entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and...

Apr 30, 2015, 16:30 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen associated with the...

Apr 29, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Webcast Alert: Isis Pharmaceuticals' First Quarter 2015 Financial Results Conference Call

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' First Quarter 2015 Financial...

Apr 22, 2015, 16:06 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Reports Positive Data From ISIS-TTR Rx in Patients With TTR Amyloidosis

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive data from an ongoing open-label extension (OLE) study of ISIS-TTRRx in patients...

Apr 10, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Present at Upcoming Investor Conferences

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at...

Mar 23, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Reports Positive Phase 1 Data on Isis-ANGPTL3Rx

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from a Phase 1 study with ISIS-ANGPTL3Rx.  In this study,...

Mar 06, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $9 million milestone payment from Biogen Idec related to...

Mar 02, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $15 million milestone payment from GSK related to advancing the...

Feb 27, 2015, 09:30 ET
Isis Pharmaceuticals, Inc.

Isis Reports Financial Results and Highlights for 2014

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced it significantly outperformed both its pro forma net operating loss (NOL) guidance and...

Feb 24, 2015, 10:46 ET
Isis Pharmaceuticals, Inc.

ISIS Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions in Prekallikrein Levels

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from a Phase 1 study with ISIS-PKKRx.  In this study, healthy...